Dr. Sujatha Nallapareddy

Oncology
701 E Hampden Ave, Ste 210, 
Littleton, CO 
Accepting New Patients
Offers Telehealth
701 E Hampden Ave, Ste 210, 
Littleton, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sujatha Nallapareddy is an Oncologist in Littleton, Colorado. Dr. Nallapareddy is rated as an Experienced provider by MediFind in the treatment of Urticaria Pigmentosa. Her top areas of expertise are Pulmonary Embolism, Thrombocytopenia, Deep Vein Thrombosis, and Antiphospholipid Syndrome. Dr. Nallapareddy is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Osmania Medical College
Residency
State University of New York at Buffalo
Specialties
Oncology
Licenses
Internal Medicine in CO
Board Certifications
Internal Medicine-American Board Of Internal Medicine (ABIM)
Hematology-American Board Of Internal Medicine (ABIM)
Medical Oncology-American Board Of Internal Medicine (ABIM)
Fellowships
University of Colorado School of Medicine (CU University of Colorado Anschutz Medical Campus)
Hospital Affiliations
The Medical Center Of Aurora & South Hospital
Littleton Adventist Hospital, Centura Health
Kit Carson County Memorial Hospital
Hca-Healthone Dba Swedish Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Rocky Mountain Cancer Centers LLP
701 E Hampden Ave, Ste 210, Littleton, CO 80120

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

3 Total Publications

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Journal: The Lancet. Oncology
Published: July 19, 2012
Similar Doctors
Experienced in Urticaria Pigmentosa
Dr. Michael D. Stone
Oncology | Hematology Oncology | Hematology
Experienced in Urticaria Pigmentosa
Dr. Michael D. Stone
Oncology | Hematology Oncology | Hematology

Poudre Valley Medical Group LLC

1925 Mountain View Ave, 
Longmont, CO 
 (46.9 miles away)
303-776-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Stone is an Oncologist and a Hematologist Oncology provider in Longmont, Colorado. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Urticaria Pigmentosa. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Stone is currently accepting new patients.

Experienced in Urticaria Pigmentosa
Dr. Eiko T. Browning
Oncology
Experienced in Urticaria Pigmentosa
Dr. Eiko T. Browning
Oncology

Rocky Mountain Cancer Centers LLP - Thornton Radiation

8820 Huron St, 
Thornton, CO 
 (23.5 miles away)
303-386-7658
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eiko Browning is an Oncologist in Thornton, Colorado. Dr. Browning is rated as an Advanced provider by MediFind in the treatment of Urticaria Pigmentosa. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, HER-2 Positive Breast Cancer, and Lung Cancer. Dr. Browning is currently accepting new patients.

Experienced in Urticaria Pigmentosa
Dr. Robert M. Jotte
Hematology | Oncology
Experienced in Urticaria Pigmentosa
Dr. Robert M. Jotte
Hematology | Oncology

Rocky Mountain Cancer Centers LLP

1800 Williams St, Ste 200, 
Denver, CO 
 (15.7 miles away)
303-388-4876
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Jotte is a Hematologist and an Oncologist in Denver, Colorado. Dr. Jotte is rated as a Distinguished provider by MediFind in the treatment of Urticaria Pigmentosa. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Jotte is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nallapareddy's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile